Correlation Between Enzyme Activity and Substrate Storage in a Cell Culture Model System for Gaucher Disease

Overview

Journal J Inherit Metab Dis

Publisher Wiley

Date 2005 Jan 27

PMID 15669681

Citations 43

Authors

U H Schueler

T Kolter

C R Kaneski

G C Zirzow

K Sandhoff

R O Brady

Affiliations

Soon will be listed here.

Abstract

Gaucher disease, the most common sphingolipidosis, is caused by a decreased activity of glucosylceramide beta-glucosidase, resulting in the accumulation of glucosylceramide in macrophage-derived cells known as Gaucher cells. Much of the storage material is thought to originate from the turnover of cell membranes, such as phagocytosed red and white blood cells. In this study, an in vitro model of Gaucher disease was developed by treating the murine macrophage cell line J774 with a specific inhibitor of glucosylceramide beta-glucosidase, conduritol B-epoxide, and feeding red blood cell ghosts, in order to mimic the disease state. It was found in this model system that glucosylceramide beta-glucosidase activity could be reduced to about 11-15% of the normal control level before increased storage of glucosylceramide occurred. This in vitro system allows insight into the correlation between enzyme activity and lipid storage as predicted by the theory of residual enzyme activity that was proposed by Conzelmann and Sandhoff.

Citing Articles

High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson's disease.

Williams D, Glasstetter L, Jong T, Chen T, Kapoor A, Zhu S Proc Natl Acad Sci U S A. 2024; 121(42):e2406009121.

PMID: 39388267 PMC: 11494340. DOI: 10.1073/pnas.2406009121.

Intrinsic link between PGRN and Gba1 D409V mutation dosage in potentiating Gaucher disease.

Lin Y, Zhao X, Liou B, Fannin V, Zhang W, Setchell K Hum Mol Genet. 2024; 33(20):1771-1788.

PMID: 39101473 PMC: 11458007. DOI: 10.1093/hmg/ddae113.

Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson's Disease.

Kopytova A, Rychkov G, Cheblokov A, Grigoreva E, Nikolaev M, Yarkova E Int J Mol Sci. 2023; 24(10).

PMID: 37240451 PMC: 10219579. DOI: 10.3390/ijms24109105.

Gastrointestinal Manifestations of Adult Cystinosis in Iran: A Descriptive Study.

Nakhaie S, Sadat Sharif A, Hosseini Shamsabadi R, Otukesh H, Hashemipour M, Mohammadi S Med J Islam Repub Iran. 2022; 36:15.

PMID: 35999937 PMC: 9386769. DOI: 10.47176/mjiri.36.15.

Splicing Modulation as a Promising Therapeutic Strategy for Lysosomal Storage Disorders: The Mucopolysaccharidoses Example.

Santos J, Goncalves M, Matos L, Moreira L, Carvalho S, Prata M Life (Basel). 2022; 12(5).

PMID: 35629276 PMC: 9146820. DOI: 10.3390/life12050608.

References

Wilkening G, Linke T, Sandhoff K . Lysosomal degradation on vesicular membrane surfaces. Enhanced glucosylceramide degradation by lysosomal anionic lipids and activators. J Biol Chem. 1998; 273(46):30271-8. DOI: 10.1074/jbc.273.46.30271. View

Coleman P, Fishman P, Brady R, Todaro G . Altered ganglioside biosynthesis in mouse cell cultures following transformation with chemical carcinogens and x-irradiation. J Biol Chem. 1975; 250(1):55-60. View

Stephens M, Bernatsky A, LEGLER G, Kanfer J . The Gaucher mouse: additional biochemical alterations. J Neurochem. 1979; 32(3):969-72. DOI: 10.1111/j.1471-4159.1979.tb04582.x. View

Cox T, Lachmann R, Hollak C, Aerts J, Van Weely S, Hrebicek M . Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000; 355(9214):1481-5. DOI: 10.1016/S0140-6736(00)02161-9. View

Conzelmann E, Sandhoff K . Partial enzyme deficiencies: residual activities and the development of neurological disorders. Dev Neurosci. 1983; 6(1):58-71. DOI: 10.1159/000112332. View

Newburg D, Shea T, Yatziv S, Raghavan S, McCluer R . Macrophages exposed in vitro to conduritol B epoxide resemble Gaucher cells. Exp Mol Pathol. 1988; 48(3):317-23. DOI: 10.1016/0014-4800(88)90068-8. View

Yatziv S, Newburg D, Livni N, Barfi G, Kolodny E . Gaucher-like changes in human blood-derived macrophages induced by beta-glucocerebrosidase inhibition. J Lab Clin Med. 1988; 111(4):416-20. View

Brady R, Kanfer J, Shapiro D . METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE. Biochem Biophys Res Commun. 1965; 18:221-5. DOI: 10.1016/0006-291x(65)90743-6. View

Stephens M, Bernatsky A, Burachinsky V, LEGLER G, Kanfer J . The Gaucher mouse: differential action of conduritol B epoxide and reversibility of its effects. J Neurochem. 1978; 30(5):1023-7. DOI: 10.1111/j.1471-4159.1978.tb12395.x. View

10.

Miller S, Zirzow G, Doppelt S, Brady R, Barton N . Analysis of the lipids of normal and Gaucher bone marrow. J Lab Clin Med. 1996; 127(4):353-8. DOI: 10.1016/s0022-2143(96)90183-3. View

11.

Smith P, Krohn R, Hermanson G, Mallia A, Gartner F, Provenzano M . Measurement of protein using bicinchoninic acid. Anal Biochem. 1985; 150(1):76-85. DOI: 10.1016/0003-2697(85)90442-7. View

12.

Leinekugel P, Michel S, Conzelmann E, Sandhoff K . Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet. 1992; 88(5):513-23. DOI: 10.1007/BF00219337. View

13.

Sawkar A, Cheng W, Beutler E, Wong C, Balch W, Kelly J . Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A. 2002; 99(24):15428-33. PMC: 137733. DOI: 10.1073/pnas.192582899. View

14.

Suzuki K . Enzymic diagnosis of sphingolipidoses. Methods Enzymol. 1978; 50:456-88. DOI: 10.1016/0076-6879(78)50049-9. View

15.

HAKOMORI S, Murakami W . Glycolipids of hamster fibroblasts and derived malignant-transformed cell lines. Proc Natl Acad Sci U S A. 1968; 59(1):254-61. PMC: 286029. DOI: 10.1073/pnas.59.1.254. View

16.

Ullman M, McCluer R . Quantitative analysis of plasma neutral glycosphingolipids by high performance liquid chromatography of their perbenzoyl derivatives. J Lipid Res. 1977; 18(3):371-8. View

17.

RADIN N . Inhibitors and stimulators of glucocerebroside metabolism. Prog Clin Biol Res. 1982; 95:357-83. View

18.

von der Heul C, Kroos M, von Eijk H . The uptake of iron by reticulocytes. The influence of purification of the ghosts on iron-containing components in the ghost suspension. Biochim Biophys Acta. 1980; 601(3):572-83. DOI: 10.1016/0005-2736(80)90559-3. View

19.

Sandhoff K, Kolter T . Biosynthesis and degradation of mammalian glycosphingolipids. Philos Trans R Soc Lond B Biol Sci. 2003; 358(1433):847-61. PMC: 1693173. DOI: 10.1098/rstb.2003.1265. View

20.

Walkley S . Cellular pathology of lysosomal storage disorders. Brain Pathol. 1998; 8(1):175-93. PMC: 8098147. DOI: 10.1111/j.1750-3639.1998.tb00144.x. View